The significance of vasoactive intestinal peptide in immunomodulation

被引:349
作者
Delgado, M
Pozo, D
Ganea, D
机构
[1] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain
[2] Univ Seville, Dept Bioquim & Biol Mol, Seville, Spain
[3] Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA
关键词
D O I
10.1124/pr.56.2.7
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
First identified by Said and Mutt some 30 years ago, the vasoactive intestinal peptide ( VIP) was originally isolated as a vasodilator peptide. Subsequently, its biochemistry was elucidated, and within the 1st decade, their signature features as a neuropeptide became consolidated. It did not take long for these insights to permeate the field of immunology, out of which surprising new attributes for VIP were found in the last years. VIP is rapidly transforming into something more than a mere hormone. In evolving scientifically from a hormone to a novel agent for modifying immune function and possibly a cytokine-like molecule, VIP research has engaged many physiologists, molecular biologists, biochemists, endocrinologists, and pharmacologists and it is a paradigm to explore mutual interactions between neural and neuroendocrine links in health and disease. The aim of this review is firstly to update our knowledge of the cellular and molecular events relevant to VIP function on the immune system and secondly to gather together recent data that support its role as a type 2 cytokine. Recognition of the central functions VIP plays in cellular processes is focusing our attention on this "very important peptide" as exciting new candidates for therapeutic intervention and drug development.
引用
收藏
页码:249 / 290
页数:42
相关论文
共 546 条
[1]
Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease [J].
Abad, C ;
Martinez, C ;
Juarranz, MG ;
Arranz, A ;
Leceta, J ;
Delgado, M ;
Gomariz, RP .
GASTROENTEROLOGY, 2003, 124 (04) :961-971
[2]
Pituitary adenylate-cyclase-activating polypeptide expression in the immune system [J].
Abad, C ;
Martinez, C ;
Leceta, J ;
Juarranz, MG ;
Delgado, M ;
Gomariz, RP .
NEUROIMMUNOMODULATION, 2002, 10 (03) :177-186
[3]
HOMOLOGOUS AND HETEROLOGOUS REGULATION OF THE HELODERMIN VASOACTIVE-INTESTINAL-PEPTIDE RESPONSE IN THE MURINE RADIATION LEUKEMIA-VIRUS-INDUCED LYMPHOMA CELL-LINE BL/VL3 [J].
ABELLO, J ;
DAMIEN, C ;
ROBBERECHT, P ;
HOOGHE, R ;
VANDERMEERS, A ;
VANDERMEERSPIRET, MC ;
CHRISTOPHE, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1989, 183 (02) :269-274
[4]
EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[5]
Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin [J].
Agnello, D ;
Bertini, R ;
Sacco, S ;
Meazza, C ;
Villa, P ;
Ghezzi, P .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1998, 275 (05) :E757-E762
[6]
Ahmed AA, 1998, SCAND J IMMUNOL, V48, P79
[7]
Desensitization, internalization, and signaling functions of β-arrestins demonstrated by RNA interference [J].
Ahn, S ;
Nelson, CD ;
Garrison, TR ;
Miller, WE ;
Lefkowitz, RJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1740-1744
[8]
Toll-like receptors: critical proteins linking innate and acquired immunity [J].
Akira, S ;
Takeda, K ;
Kaisho, T .
NATURE IMMUNOLOGY, 2001, 2 (08) :675-680
[9]
SELECTIVE LOCALIZATION OF VASOACTIVE-INTESTINAL-PEPTIDE AND SUBSTANCE-P IN HUMAN EOSINOPHILS [J].
ALIAKBARI, J ;
SREEDHARAN, SP ;
TURCK, CW ;
GOETZL, EJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 148 (03) :1440-1445
[10]
Cutting edge:: Biasing immune responses by directing antigen to macrophage Fcγ receptors [J].
Anderson, CF ;
Mosser, DM .
JOURNAL OF IMMUNOLOGY, 2002, 168 (08) :3697-3701